<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cayman Journal - Aprea Therapeutics Inc (APRE)</title>
    <description>Latest news, press releases, and SEC filings for Aprea Therapeutics Inc (APRE)</description>
    <link>https://caymanjournal.com/stock/APRE</link>
    <language>en-us</language>
    
    <copyright>Copyright 2026, Cayman Journal</copyright>
    <managingEditor>editorial@caymanjournal.com (Editorial Team)</managingEditor>
    <webMaster>webmaster@caymanjournal.com (Web Master)</webMaster>
    <lastBuildDate>Mon, 27 Apr 2026 21:42:36 GMT</lastBuildDate>
    <ttl>60</ttl>
    <atom:link href="https://caymanjournal.com/stock/APRE/feed.xml" rel="self" type="application/rss+xml" />
    <image>
      <url>https://caymanjournal.com/logo.png</url>
      <title>Cayman Journal</title>
      <link>https://caymanjournal.com</link>
      <width>144</width>
      <height>144</height>
    </image>

    <item>
      <title>S-3 — Aprea Therapeutics, Inc.</title>
      <description># 📄 What This Document Is 📜
This is an S-3 Registration Statement, a major SEC filing that tells investors exactly what shares are available and under what conditions. Unlike a typical earnings report, this document is focused entirely on the potential *sale* of company stock and warrants by exist</description>
      <link>https://caymanjournal.com/stock/APRE/sec-filing/0001104659-26-046900</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/APRE/sec-filing/0001104659-26-046900</guid>
      <pubDate>Wed, 22 Apr 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item><item>
      <title>PRE 14A — Aprea Therapeutics, Inc.</title>
      <description># 🧾 What This Document Is 📄
This is a Preliminary Proxy Statement (PRE 14A), which is a highly technical document filed with the SEC. Essentially, it’s the official homework assignment for the company&apos;s shareholders. It informs you about the upcoming 2026 Annual Meeting of Stockholders and outline</description>
      <link>https://caymanjournal.com/stock/APRE/sec-filing/0001104659-26-045158</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/APRE/sec-filing/0001104659-26-045158</guid>
      <pubDate>Mon, 20 Apr 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item><item>
      <title>8-K — Aprea Therapeutics, Inc.</title>
      <description># 🧾 What This Document Is
This is a Form 8-K filing, which companies use to announce major events to investors. Attached is a press release announcing that Aprea Therapeutics has closed a **$30 million private funding round**. This isn&apos;t a regular stock sale to the public; it was a direct deal with</description>
      <link>https://caymanjournal.com/stock/APRE/sec-filing/0001104659-26-038258</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/APRE/sec-filing/0001104659-26-038258</guid>
      <pubDate>Wed, 01 Apr 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item><item>
      <title>8-K — Aprea Therapeutics, Inc.</title>
      <description># 🧾 What This Document Is
This is an 8-K filing from **Aprea Therapeutics, Inc. (APRE)**. It contains the full legal contract (Exhibit 10.1) for a **private investment deal**. Essentially, the company is selling stock and warrants directly to a group of investors to raise money. This isn&apos;t a public</description>
      <link>https://caymanjournal.com/stock/APRE/sec-filing/0001104659-26-036821</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/APRE/sec-filing/0001104659-26-036821</guid>
      <pubDate>Mon, 30 Mar 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item>
  </channel>
</rss>